Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Shenoy, Y. Qi, D. Gupta, M. Katovich, M. Raizada (Gainesville, United States Of America). Small moleculae ACE2 activator, diminazene aceturate attenuates bleomycin-induced pulmonary fibrosis. Eur Respir J 2012; 40: Suppl. 56, 1765

Member's Comments

No comment yet.

Related content which might interest you: Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012 The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 461s Year: 2005 The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2002; 19: 1124-1127 Year: 2002 The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Effects of aerosolized earthworm fibrinolytic enzyme on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 766s Year: 2006 The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010 Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Effects of drotrecogin-alpha on the bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Danshenextract salt Inhibits bleomycin-induced experimental pulmonary fibrosis Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020